Sarepta Therapeutics Faces Regulatory Setback with Gene Therapy Safety Warnings

Sarepta Therapeutics finds itself navigating significant regulatory challenges as the U.S. Food and Drug Administration has imposed the most serious safety designation on the company’s gene therapy ELEVIDYS. The agency has mandated a black box warning—the strongest safety alert in pharmaceutical labeling—highlighting risks of severe liver injury that could progress to acute liver failure. This regulatory action comes in response to safety concerns that emerged following the treatment’s initial market approval.

Beyond the immediate regulatory pressures, Sarepta’s financial stability has come under scrutiny. The company currently holds an Altman Z-Score of -0.22, placing it firmly within what financial analysts term the “distress zone.” This metric suggests Read more...